PreMD loses Amex support
Predictive medicine company (PreMD; Toronto) said it has been notified by the American Stock Exchange (Amex) that it will not continue to support PreMD's plan for regaining compliance with the continued listing standards and that it intends to delist the company's common stock from the exchange by filing a delisting application with the SEC pursuant to Section 1009(d) of the Amex company guide. The determination by the staff of the Amex to initiate the delisting of the common stock from the Amex is based on the company's failure to meet several of the exchange's conditions for continued listing.
PreMD specializes in predictive medicine, and is dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases.
China Sky One listed on Amex
China Sky One Medical (Harbin, China) said that its common shares have been approved for listing on the American Stock Exchange (AMEX). The company expects to begin trading on AMEX under the symbol "CSY." This approval is contingent upon China Sky One Medical being in compliance with all applicable listing standards on the date it begins trading on the Amex and may be rescinded if China Sky One Medical is not in compliance with such standards. Concurrent with its first trade on AMEX, China Sky One Medical will no longer be quoted on the Over-the-Counter Bulletin Board.
China Sky One Medical makes pharmaceutical, medicinal and diagnostic kit products.
Atherotech test covered by Tricare
Atherotech (Brimingham, Alabama) said that its VAP cholesterol test is now covered by Tricare, the Department of Defense's healthcare plan for the uniformed services, retirees and their families.
The announcement means that the VAP Test will now be available to the more than 9 million beneficiaries enrolled in the Military Health System (MHS) through Tricare. The MHS provides quality medical care through a network of providers, military treatment facilities, medical clinics and dental clinics worldwide.
The VAP Test directly measures LDL. Atherotech says the test also is the only commercially available test that meets new American Diabetes Association and American College of Cardiology (ADA-ACC) cholesterol guidelines for people at high risk of heart attack and stroke (including people with Type 2 diabetes). The ADA-ACC consensus statement establishes measurement and treatment guidelines for apoB in addition to LDL and non-HDL in high-risk patients.